Jublia efinaconazole regulatory update

Kaken's marketing partner Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) said FDA approved an NDA for Jublia efinaconazole to treat onychomycosis of the toenails. Th...